SynthesisBMC cancer2023

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics.

Wenjie Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.